Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.51 |
| ▸ | POLB | P06746 | 1/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | HPGD | P15428 | 1/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.50 |
| ▸ | PPID | Q08752 | 2/20 | 0.40 |
| ▸ | DHFR | P00374 | 4/20 | 0.39 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.38 |
| ▸ | TYMS | P04818 | 1/20 | 0.38 |
| ▸ | NOD2 | Q9HC29 | 1/20 | 0.38 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.37 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6448822 | 1.00 | L3MBTL1 (0.53) | L3MBTL1KMT2APOLBKDM4EALDH1A1 | |
| SCHEMBL27519961 | 1.00 | L3MBTL1 (0.53) | L3MBTL1KMT2APOLBKDM4EALDH1A1 | |
| SCHEMBL10828794 | 0.88 | L3MBTL1 (0.56) | L3MBTL1KMT2APOLBKDM4EALDH1A1 | |
| SCHEMBL10828801 | 0.88 | L3MBTL1 (0.56) | L3MBTL1KMT2APOLBKDM4EALDH1A1 | |
| SCHEMBL9556474 | 0.86 | L3MBTL1 (0.53) | L3MBTL1KMT2APOLBKDM4EALDH1A1 | |
| SCHEMBL9556468 | 0.86 | L3MBTL1 (0.53) | L3MBTL1KMT2APOLBKDM4EALDH1A1 | |
| SCHEMBL9555886 | 0.85 | L3MBTL1 (0.52) | L3MBTL1KMT2APOLBKDM4EALDH1A1 | |
| SCHEMBL9555878 | 0.85 | L3MBTL1 (0.52) | L3MBTL1KMT2APOLBKDM4EALDH1A1 | |
| SCHEMBL9601134 | 0.83 | L3MBTL1 (0.49) | L3MBTL1KMT2APOLBKDM4EALDH1A1 | |
| SCHEMBL9782470 | 0.82 | ALOX5 (0.36) | DHFRALOX5TYMS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6855712-B2 | Combination of benzoquinazoline antifolates and protecting agents | SMITHKLINE BEECHAM CORPORATION (US) | 2005-02-15 | — | — | US | disclosed |
| US-6762188-B1 | INHIBITING THYMIDYLATE SYNTHASE; COLON, BREAST OR LUNG CARCINOMA | SMITHKLINE BEECHAM CORPORATION | 2004-07-13 | — | — | US | disclosed |
| EP-1199307-B1 | Pharmaceutically active benzoquinazoline compounds | WELLCOME FOUND (GB) | 2004-02-25 | — | — | EP | disclosed |
| US-20030203924-A1 | Novel combination of benzoquinazoline antifolates and protecting agents | SMITH GARY KEITH (US) | 2003-10-30 | — | — | US | disclosed |
| US-6579877-B2 | Reducing intestinal toxicity of a noncompetitive thymidylate synthase inhibitor by co-administering a folate derivative without blocking therapy; anticancer, antitumore agents | SMITHKLINE BEECHAM CORPORATION | 2003-06-17 | — | — | US | disclosed |
| US-20020137748-A1 | Novel combination of benzoquinazoline antifolates and protecting agents | SMITH GARY KEITH (US) | 2002-09-26 | — | — | US | disclosed |
| EP-1199307-A1 | Pharmaceutically active benzoquinazoline compounds | THE WELLCOME FOUNDATION LIMITED (GB) | 2002-04-24 | — | — | EP | disclosed |
| US-6358952-B1 | SIDE EFFECT REDUCTION WHEN ADMINISTERING NON-COMPETITIVE THYMIDYLATE SYNTHASE INHIBITOR AS ANTITUMOR AGENT | SMITHKLINE BEECHAM CORPORATION | 2002-03-19 | — | — | US | disclosed |
| US-6090941-A | Pharmaceutically active benzoquinazoline compounds | GLAXO WELLCOME INC. (US) | 2000-07-18 | — | — | US | disclosed |
| EP-0675719-B1 | NOVEL COMBINATION OF BENZOQUINAZOLINE ANTIFOLATES AND PROTECTING AGENTS | WELLCOME FOUND (GB) | 1998-06-10 | — | — | EP | disclosed |
| US-5405851-A | Administering benzoquinazoline thymidylate synthase inhibitors | BURROUGHS WELLCOME CO. (US) | 1995-04-11 | — | — | US | disclosed |
| WO-1994014448-A1 | NOVEL COMBINATION OF BENZOQUINAZOLINE ANTIFOLATES AND PROTECTING AGENTS | THE WELLCOME FOUNDATION LIMITED (GB) | 1994-07-07 | — | — | WO | disclosed |
| US-5236927-A | Reduced toxicity; side effect reduction | NATIONAL RESEARCH DEVELOPMENT CORPORATION (GB) | 1993-08-17 | — | — | US | disclosed |
| EP-0535034-A1 | PHARMACEUTICALLY ACTIVE BENZOQUINAZOLINE COMPOUNDS | THE WELLCOME FOUNDATION LIMITED (GB) | 1993-04-07 | — | — | EP | disclosed |
| EP-0204529-B1 | ANTI-CANCER QUINAZOLINE DERIVATIVES | BTG INTERNATIONAL LIMITED (GB) | 1993-03-31 | — | — | EP | disclosed |
| US-5187167-A | Antitumor agents | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1993-02-16 | — | — | US | disclosed |
| US-5081124-A | Amino acid and polyamino acid derivatives, inhibitors of thymidylate synthetase | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1992-01-14 | — | — | US | disclosed |
| WO-1991019700-A1 | PHARMACEUTICALLY ACTIVE BENZOQUINAZOLINE COMPOUNDS | THE WELLCOME FOUNDATION LIMITED (GB) | 1991-12-26 | — | — | WO | disclosed |
| US-4992550-A | Thymidylate synthetase inhibitors | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1991-02-12 | — | — | US | disclosed |
| EP-0204529-A2 | Anti-cancer quinazoline derivatives | BTG INTERNATIONAL LIMITED (GB) | 1986-12-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030203924-A1 | Novel combination of benzoquinazoline antifolates and protecting agents | SLC19A1, DHFR, FOLR2 | L3MBTL1 1558/4885KMT2A 2556/4885POLB 516/4885 |
| US-20020137748-A1 | Novel combination of benzoquinazoline antifolates and protecting agents | SLC19A1, DHFR, FOLR2 | L3MBTL1 1558/4885KMT2A 2556/4885POLB 516/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.